Market news
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
NewMediaWire Press Release.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial targeting for neffy, tighter financial discipline, and a pipeline push into chronic spontaneous urticaria. The quarter itself showed a company still early in proving […]
The average of price targets set by Wall Street analysts indicates a potential upside of 297% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.
Moby summary of ARS Pharmaceuticals, Inc.'s Q2 2026 earnings call
ARS Pharmaceuticals (NASDAQ:SPRY) outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused promotion for its neffy intranasal epinephrine product, lower operating expenses and an expected pat
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -14.55% and +5.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
$26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward targeted provider engagement, significantly reducing total operating expenses for 2H 2026 and supporting an expected path to cash flow breakeven by the end of 2027 Commercial operations strengthened with appointment of Meg Smith as Chief Commercial Officer and completed expansion of field sal
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Thursday, August 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. During the call, Donn Casale, President and Chief Executive Officer, will outline the Company’s updated strate
ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is one of the 10 best stocks under $10 that could triple. On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the company’s Co-founder and Chief Executive Officer, Richard Lowenthal, will no longer be employed by the company. Donn Casale, the company’s current President, has […]
ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.
Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.